News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|February 4, 2012

Atopic Dermatitis medications box

Clindamycin and Benzoyl Peroxide (BenzaClin)

Methylprednisolone Sodium Succinate (A-Methapred)

Triamcinolone Diacetate (Aristocort)

Fluticasone Propionate (Cutivate)

More Atopic Dermatitis

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Blur image of medical clinic | Image Credit: © whyframeshot - stock.adobe.com

Navepegritide's bone-alignment effects hold through 2 years

ByBenjamin P. Saylor

June 30th 2026

FDA expands roflumilast cream approval to children as young as 2 years with plaque psoriasis

FDA expands roflumilast cream approval to children as young as 2 years with plaque psoriasis

ByMorgan Ebert, Executive Editor

June 29th 2026

Sequential bilateral TMS linked to improvement in youth treatment-resistant depression | Image credit: © New Africa - stock.adobe.com

Sequential bilateral TMS linked to improvement in youth treatment-resistant depression

ByMorgan Ebert, Executive Editor

June 29th 2026

Pediatric clinical trial update: Q2 2026

Pediatric clinical trial update: Q2 2026

ByMorgan Ebert, Executive Editor

June 29th 2026

AAP updates guidance on pediatric iron deficiency screening and treatment | Image Credit: © nicoletaionescu - stock.adobe.com

AAP updates guidance on pediatric iron deficiency screening and treatment

ByMorgan Ebert, Executive Editor

June 29th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

AAP updates guidance on pediatric iron deficiency screening and treatment

FDA expands roflumilast cream approval to children as young as 2 years with plaque psoriasis

Pediatric clinical trial update: Q2 2026

Sequential bilateral TMS linked to improvement in youth treatment-resistant depression

FDA approves risankizumab for pediatric plaque psoriasis and psoriatic arthritis